Draupnir Bio Overview

  • Founded
  • 2017

Founded
  • Status
  • Private

  • Employees
  • 21

Employees
  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $33.2M

  • Investors
  • 7

Draupnir Bio General Information

Description

Provider of biopharmaceutical services intended to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company's services offer an array of technology, protein chemistry, and advanced carbohydrate chemistry, enabling patients to have safe and effective glycomics-based therapy.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • Ole Maaløes Vej 3
  • 2200 Copenhagen
  • Denmark
+45 51 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Draupnir Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 01-Oct-2019 $33.2M 000.00 Completed Pre-Clinical Trials
2. Grant 30-Nov-2017 00.000 Completed Pre-Clinical Trials
1. Accelerator/Incubator 01-Jan-2017 Completed Pre-Clinical Trials
To view Draupnir Bio’s complete valuation and funding history, request access »

Draupnir Bio Executive Team (7)

Name Title Board Seat Contact Info
Andrew Hotchkiss Chief Executive Officer
Camilla Gustafen Ph.D Co-Founder, Chief Scientific Officer & Vice President of Biology
Simon Glerup Ph.D Co-Founder, Chief Scientific Officer & Board Member
Anna Quattropani Ph.D Chief Discovery Officer
Casper Tind Hansen Chief Business Officer
You’re viewing 5 of 7 executive team members. Get the full list »

Draupnir Bio Board Members (6)

Name Representing Role Since
Emmanuelle Coutanceau Ph.D Novo Holdings Board Member 000 0000
Eva-Lotta Allan Draupnir Bio Chairman 000 0000
Robert Scott MD Self Board Member 000 0000
Roel Bulthuis Inkef Board Member 000 0000
Simon Glerup Ph.D Draupnir Bio Co-Founder, Chief Scientific Officer & Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Draupnir Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Draupnir Bio Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Gilde Healthcare Partners Venture Capital Minority 000 0000 000000 0
High-Tech Gründerfonds Venture Capital Minority 000 0000 000000 0
Inkef Venture Capital Minority 000 0000 000000 0
Novo Holdings Venture Capital Minority 000 0000 000000 0
Novo Nordisk Fonden Limited Partner 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »